Antipsychotic medications: a timeline of innovations and remaining challenges

Report an error

Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

This research paper outlines the evolution of antipsychotic drugs from the first introduction of chlorpromazine in 1954 to the 2024 approval of xanomeline-trospium. It finds that while newer drugs are generally safer and more effective against a broader range of symptoms, significant challenges remain regarding cognitive symptoms and long-term metabolic side effects.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • Antipsychotic medications are categorized into 'conventional' and 'atypical' groups, primarily distinguished by their side effects; conventional drugs often cause movement-related issues like spasms and tremors, whereas atypical antipsychotics are less likely to do so.
  • Chlorpromazine, introduced in the United States in 1954, was the first antipsychotic drug and led to the 'dopamine theory' of schizophrenia, which posited that the condition was caused by excess dopamine in the brain.
  • Clozapine, introduced in the US in 1990, challenged the belief that movement-related side effects were inevitable for efficacy, as it showed benefits for both psychosis and 'negative symptoms' with lower dopamine receptor action.
  • Despite improvements, most current antipsychotics struggle to treat 'negative symptoms' (emotional blunting, social withdrawal) and 'cognitive symptoms' (disorganized thoughts, memory, and attention).
  • Many modern antipsychotic drugs carry risks of long-term complications, including weight gain, diabetes, metabolic problems, and cardiovascular disease.
  • The 2024 approved medication xanomeline-trospium targets muscarinic receptors rather than dopamine receptors and has demonstrated efficacy against a broader range of schizophrenia symptoms without causing movement, metabolic, or weight-gain side effects.

Cite the original document

APA
Dattani, S. (2024). Antipsychotic medications: a timeline of innovations and remaining challenges. Our World in Data. https://ourworldindata.org/antipsychotic-medications-timeline
Chicago
Dattani, Saloni. Antipsychotic medications: a timeline of innovations and remaining challenges. Our World in Data, 2024. https://ourworldindata.org/antipsychotic-medications-timeline.
Wikipedia
{{cite report |last1=Dattani |first1=Saloni |title=Antipsychotic medications: a timeline of innovations and remaining challenges |publisher=Our World in Data |date=26 August 2024 |url=https://ourworldindata.org/antipsychotic-medications-timeline |access-date=5 November 2026 |via=Climate Insights Directory (document owid-000023)}}
BibTeX
@techreport{dattani2024antipsychotic, author = {Dattani, Saloni}, title = {{Antipsychotic medications: a timeline of innovations and remaining challenges}}, institution = {Our World in Data}, year = {2024}, month = aug, url = {https://ourworldindata.org/antipsychotic-medications-timeline}, urldate = {2026-11-05}, note = {Indexed by Climate Insights Directory, document owid-000023} }

Full text

Collected · Record updated